MEDO.ai is a healthtech startup company dual-headquartered in Edmonton, Canada, and Singapore. MEDO was founded in 2018 and has 15 full-time employees. MEDO envisions transforming ultrasound into the stethoscope of the 21st century. MEDO builds cutting-edge artificial intelligence that pairs with ultrasound devices to facilitate novice users' ability to detect common and critical conditions.
MEDO’s cloud-based ultrasound platform (ARIA), which has been cleared by the US Food and Drug Administration, is capable of segmenting anatomical structures from ultrasound images and cine clips, visualizing them in 3D and translating them into relevant clinical information in a couple of seconds.
MEDO aims to expand its 3D-ultrasound AI technology to new use cases, including Breast-AI and Liver-AI. These functionalities can be co-developed through R&D collaboration. MEDO is also looking for clinical partners or pilot users of its Thyroid-AI and Hip-AI to further enhance the technology, expand the usability based on user needs, and highlight the benefits in high-impact joint publications.